Skip to main content
Clinical Trials/NCT04645134
NCT04645134
Completed
Not Applicable

Physical Activity and Cognitive Function in Older Adults: A Novel Role for GPLD1

Pennington Biomedical Research Center1 site in 1 country25 target enrollmentApril 1, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Aging
Sponsor
Pennington Biomedical Research Center
Enrollment
25
Locations
1
Primary Endpoint
Plasma concentrations of GPLD1
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

The investigators are conducting a cross-sectional, observational study to investigate whether plasma GPLD1 concentrations are associated with higher cognitive function and better brain structure and function in two groups of older adults with high or low levels of physical activity.

Detailed Description

This is a cross-sectional, observational study which will enroll up to 28 healthy, older adults (65-85 y, BMI 20-35 kg/m2), and stratify by current self-reported physical activity level (equal inactive vs. equal highly active). Aim 1: Investigate whether physical activity level is associated with GPLD1. Aim 2: Investigate whether cognitive function and brain structure/function are associated with GPLD1.

Registry
clinicaltrials.gov
Start Date
April 1, 2021
End Date
March 17, 2022
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Eric Ravussin

Associate Executive Director for Clinical Science

Pennington Biomedical Research Center

Eligibility Criteria

Inclusion Criteria

  • Ages 65-85 y (inclusive)
  • Body mass index (BMI) of 20-35 kg/m2 (inclusive)
  • Willing to have blood and data stored for future research use

Exclusion Criteria

  • History of clinically diagnosed diabetes (Type 1 or 2) or a fasting blood glucose \>126 mg/dL
  • Diagnosed Alzheimer's disease, dementia, or related-brain diseases
  • Chronic use of atypical antipsychotic or bipolar medications
  • Initiation of novel pharmacotherapy agents (such as antidepressant, hypertension, or dyslipidemia) within the last 3 months
  • Uncontrolled hypertension (blood pressure \>160 systolic or \>110 diastolic)
  • Asthma that limits the ability to participate in moderate to vigorous physical activity or requiring systemic glucocorticoid administration
  • Emphysema that limits the ability to participate in moderate to vigorous physical activity or requiring systemic glucocorticoid administration
  • Current alcohol use exceeding 14 drinks per week in women, exceeding 21 drinks per week in men, having treatment for alcohol abuse in the last year, or having treatment for alcohol abuse more than 1 year ago (but with inability to refrain from alcohol in the past year)
  • Use of illegal drugs or marijuana within 1-month of completing a Screening Visit; treatment for drug addiction in the 1-year or having treatment for drug addiction \>1-year ago, but with an inability to refrain from the drug of addiction in the 1-year
  • Unwilling to abstain from illegal drugs and marijuana for the duration of the study

Outcomes

Primary Outcomes

Plasma concentrations of GPLD1

Time Frame: 1 day

Plasma GPLD1 (by a blood draw) is performed.

Secondary Outcomes

  • Physical activity level(7 days)
  • Brain activity and function(1 day)
  • Total grey matter volume(1 day)
  • Cognitive function(1 day)

Study Sites (1)

Loading locations...

Similar Trials